Blog

Since September 2014, the fixed-dose combination of dolutegravir/abacavir/lamivudine (trade name Triumeq) has been approved for human immunodeficiency virus (HIV) infected ...

The European Commission on Friday cleared a German scheme that allowed exceptions to be made for pharmaceutical groups whose medicines ...

Canagliflozin (Invokana) has been approved since November 2013 for use as monotherapy and in various combination therapies for adults with type 2 iabetes mellitus, ...

Sipuleucel-T (trade name Provenge) has been approved since September 2014 for men with metastatic prostate cancer who have few or ...

[:content [\1 \7 \space \M \a \r \c \h \space \2 \0 \1 \4 \space \- \  \T \h \e \space \G \e \r \m \a \n \space \I \n \s \t \i \t \u \t \e \space \f \o \r \space \Q \u \a \l \i \t \y \space \a \n \d \space \E \f \f \i \c \i \e \n \c \y \space \i \n \space \H \e \a \l \t \h \space \C \a \r \e \space \( \I \Q \W \i \G \) \space \a \l \r \e \a \d \y \space \a \s \s \e \s \s \e \d \space \t \h \e \space \a \d \d \e \d \space \b \e \n \e \f \i \t \space \o \f " ..."]]

Germany has come top of a new international league table in terms of access to medicines for patient organisations, with ...

Germany’s IQWiG has concluded that Eisai’s breast cancer drug Halaven (erbulin mesylate) does indeed offer a benefit over other comparators on ...

Gilead Sciences has finally agreed a price of for its hepatitis C virus (HCV) therapy Sovaldi with Germany's main health ...

The German Institute for Quality and Efficiency in Health Care (IQWiG) has assessed documents subsequently submitted by the drug manufacturer ...

2 January 2015 - Idelalisib (trade name Zydelig) has been available since September 2014 for use by patients with follicular lymphoma or chronic ...

Daclatasvir dihydrochloride (trade name Daklinza) has been approved since August 2014 for the treatment of adults with chronic hepatitis C ...

5 December 2013 - Enzalutamide (Xtandi) has been approved since June 2013 for men with metastatic prostate cancer in whom the ...

Japan-based Eisia said it was “outraged” with IQWIG's view that Fycompa (perampanel) offered no additional benefit for epilepsy and should ...